A retrospective longitudinal study to examine the factors associated with the prescribing of oral fingolimod among individuals with Multiple Sclerosis in the initial years after market approval
Latest Information Update: 09 Mar 2021
At a glance
- Drugs Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 28 Feb 2021 Results (n=1997) published in the Pharmacotherapy
- 23 May 2020 New trial record
- 20 May 2020 Results presented at the 25th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research